United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - gabapentin - oral capsule - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - gabapentin - oral capsule - 300mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - gabapentin - oral capsule - 400mg

Israel - English - Ministry of Health

medison pharma ltd - amifampridine - tablets - amifampridine 10 mg - amifampridine - symptomatic treatment of lambert-eaton myasthenic syndrome (lems) in adults

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - alglucosidase alfa - injection, powder, lyophilized, for solution - 52.5 mg - alglucosidase alfa 50 mg/vial

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - laronidase - injection, solution - 2.9mg - laronidase 2.9mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genzyme therapeutics ltd - alglucosidase alfa - powder for solution for infusion - 50mg

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - riociguat, quantity: 1 mg - tablet, film coated - excipient ingredients: hypromellose; crospovidone; lactose monohydrate; hyprolose; sodium lauryl sulfate; microcrystalline cellulose; magnesium stearate; propylene glycol; titanium dioxide; iron oxide yellow - pulmonary arterial hypertension:,adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:,? idiopathic pulmonary arterial hypertension,? heritable pulmonary arterial hypertension,? pulmonary arterial hypertension associated with connective tissue diseases or,? pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, lll or iv symptoms,chronic thromboembolic pulmonary hypertension:,adempas is indicated for the treatment of:,persistent or recurrent chronic thromboembolic pulmonary hypertension (cteph) after surgical treatment or,inoperable cteph in adult patients with who functional class ii, lll or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - riociguat, quantity: 2 mg - tablet, film coated - excipient ingredients: titanium dioxide; hypromellose; sodium lauryl sulfate; hyprolose; magnesium stearate; lactose monohydrate; iron oxide red; iron oxide yellow; microcrystalline cellulose; propylene glycol; crospovidone - pulmonary arterial hypertension:,adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:,? idiopathic pulmonary arterial hypertension,? heritable pulmonary arterial hypertension,? pulmonary arterial hypertension associated with connective tissue diseases or,? pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, lll or iv symptoms,chronic thromboembolic pulmonary hypertension:,adempas is indicated for the treatment of:,persistent or recurrent chronic thromboembolic pulmonary hypertension (cteph) after surgical treatment or,inoperable cteph in adult patients with who functional class ii, lll or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - riociguat, quantity: 1.5 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; lactose monohydrate; propylene glycol; microcrystalline cellulose; hypromellose; magnesium stearate; titanium dioxide; crospovidone; hyprolose; iron oxide yellow - pulmonary arterial hypertension:,adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:,? idiopathic pulmonary arterial hypertension,? heritable pulmonary arterial hypertension,? pulmonary arterial hypertension associated with connective tissue diseases or,? pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, lll or iv symptoms,chronic thromboembolic pulmonary hypertension:,adempas is indicated for the treatment of:,persistent or recurrent chronic thromboembolic pulmonary hypertension (cteph) after surgical treatment or,inoperable cteph in adult patients with who functional class ii, lll or iv symptoms